Benralizumab is an Interleukin-5 receptor antagonist indicated for which age group?

Benralizumab is an interleukin-5 receptor antagonist that is primarily used for the treatment of severe asthma in patients with an eosinophilic phenotype. The indication for Benralizumab is specifically for children aged 12 years and older, adolescents, and adults. This age designation is critical because the medication has been thoroughly studied and shown to be effective and safe within this age group based on clinical trials.

For younger children, such as those under 12 years of age, the available data may not provide sufficient safety or efficacy evidence to support its use. That's why options indicating age groups younger than 12 years, or claiming that it’s approved for all ages, do not align with the specific indications for Benralizumab. The distinction in age requirements ensures that the recommendations for treatment are supported by adequate clinical evidence, thus optimizing patient safety and treatment outcomes.